Potential impact of a nine-valent vaccine in human papillomavirus related cervical diseaseReport as inadecuate




Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease - Download this document for free, or read online. Document in PDF available to download.

Infectious Agents and Cancer

, 7:38

HPV Prevention

Abstract

BackgroundInformation on human papillomavirus HPV type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution RC to invasive cervical cancer ICC and precancerous cervical lesions of the nine HPV types HPV 6-11-16-18-31-33-45-52-58 included in an HPV vaccine currently under development.

MethodsEstimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases.

ResultsRC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31-33-45-52-58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas SCC and 95.5% in adenocarcinomas ADC. HPV 16-18-45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age trend test p<0.0001, driven by the decrease in older ages of HPV 16-18-45. In contrast, the RC of HPV 31-33-52-58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025.

The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC.

ConclusionsThe addition of HPV 31-33-45-52-58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.

KeywordsHuman papillomavirusCervical cancerGenotypeEpidemiologyHuman papillomavirus vaccinesElectronic supplementary materialThe online version of this article doi:10.1186-1750-9378-7-38 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: BeatrizSerrano - LaiaAlemany - SaraTous - LaiaBruni - GaryMClifford - ThomasWeiss - FrancescXavierBosch - Silviade Sanjos

Source: https://link.springer.com/







Related documents